ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1342	National Cancer Institute	Html	en	Secondhand Smoke and Cancer	A fact sheet that summarizes the studies on the health effects of exposure to environmental (secondhand) tobacco smoke.	safe level 0.379875 passive smoke 0.502001 Human Services 0.468341 nonsmoking adults 0.357216 secondhand tobacco smoke 0.68104 U.S. Department 0.464191 lung cancer 0.378247 Cancer Progress Report 0.355171 burning tobacco product 0.42493 secondhand smoke 0.997055 Environmental Health Hazard 0.364487 Tobacco Control Monograph 0.372592 tobacco smoke 0.693112 U.S. Surgeon General 0.402428 Tobacco Smoke Causes 0.494425 tobacco products 0.362817 nationwide health promotion 0.362703 Environmental Tobacco Smoke—ETS 0.377837 Environmental Protection Agency 0.465583 contain harmful chemicals 0.358856 health effects 0.390654 disease prevention agenda 0.353662 United States 0.418836 National Toxicology Program 0.432935 health promotion 0.395997	U.S. Environmental Protection 0.431643 sudden infant death 0.405056 public places 0.357277 U.S. National Toxicology 0.366163 infant death syndrome 0.405701 heart disease 0.378172 smoking 0.358862 National Cancer Institute 0.4772 smoke cause cancer 0.529335 heart disease deaths 0.35595 Respiratory Health Effects 0.361324 tobacco product 0.437535 secondhand smoke exposure 0.747052 sinus cavity cancer 0.360979 health 0.407857 tobacco smoke cause 0.527224 environmental tobacco smoke 0.625449 Chronic Disease Prevention 0.389 lung cancer deaths 0.360096 Surgeon General 0.4042 Public Health Service 0.390186 involuntary smoke 0.507716 ear infections 0.356303 testing indoor air 0.35347	CLICK HERE
1663	National Cancer Institute	Html	en	Childhood Astrocytomas Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood astrocytomas.	cancer treatment 0.624127 new cancer cells 0.50571 high-grade astrocytoma 0.568902 star-shaped brain cells 0.50361 metastatic brain tumors 0.515525 type 0.567046 tuberous sclerosis 0.508341 chemotherapy 0.51254 proton beam radiation 0.504515 PDQ cancer information 0.568694 clinical trial search 0.544652 brain tumors 0.664824 children 0.509721 new blood vessels 0.577461 dead tumor cells 0.517027 clinical trials 0.906249 cancer information summary 0.537035 clinical trial 0.760659 stem cell transplant 0.512502 treatment clinical trial 0.503103 radiation therapy 0.993729 Treatment Editorial Board 0.497213 beam radiation therapy 0.519746 subependymal giant cell 0.530817	treatment 0.904348 general information 0.532617 cancer cells 0.898737 conformal radiation therapy 0.568043 intensity-modulated radiation therapy 0.52166 specific cancer cells 0.501338 stereotactic radiation therapy 0.544315 childhood high-grade astrocytoma 0.500502 astrocytoma 0.619975 low-grade astrocytoma 0.590271 treatment clinical trials 0.531572 National Cancer Institute 0.535683 spinal cord 0.789593 effects cancer treatment 0.512031 new treatment 0.578461 external radiation therapy 0.577741 brain 0.729014 childhood astrocytoma 0.499108 cancer clinical trials 0.564469 checks tumor tissue 0.501876 tumor 0.802924 cancer 0.956922 information 0.571652 childhood low-grade astrocytoma 0.521596	CLICK HERE
1805	National Cancer Institute	Html	es	Tratamiento del cáncer de ano (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de ano.	Anal Cancer Trial 0.489207 results from 0.31371 John M 0.347549 with external radiotherapy 0.314904 anal canal 0.794085 combined modality therapy 0.350825 Trial Working Party 0.324488 randomized intergroup study 0.336989 Radiation Therapy Oncology 0.354467 perianal epidermoid cancers 0.314329 Radiat Oncol Biol 0.493627 anal intraepithelial neoplasia 0.3483 Natl Cancer Inst 0.358284 Flam M 0.355801 epidermoid carcinoma 0.391708 patients with 0.3347 radiation therapy 0.487367 preoperative multidisciplinary therapy 0.316168 squamous carcinoma 0.31988 intraepitelial anal ii–iii 0.32888 Krall JM 0.319145 Cancer Trial Working 0.342892 estadio ii 0.314589 Pajak TF 0.321788 Therapy Oncology Group 0.342392	with anal squamous 0.330697 anal carcinoma 0.555894 patients with carcinoma 0.314283 adjuvant combined modality 0.322897 combined with chemotherapy 0.336207 Oncology Group study 0.357157 Cancer Research 0.342768 therapy combined with 0.337029 Definitive irradiation 0.321135 randomised ukcccr anal 0.326366 interim report 0.31903 versus radiotherapy 0.314135 Clin Oncol 0.342577 Sischy B 0.347382 Oncol Biol Phys 0.504444 UK Co-ordinating Committee 0.321139 anal cancer 0.987825 definitive nonsurgical treatment 0.344247 optimal radiation 0.320998 advanced anal canal 0.329424 UKCCCR Anal Cancer 0.435954 implantation combined with 0.313892 anal canal carcinoma 0.398943 Doggett RL 0.318887	CLICK HERE
1831	National Cancer Institute	Html	es	Tratamiento del cáncer de vulva (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vulva.	Obstet Gynecol 0.804289 Lippincott Williams 0.202983 if proper radiation 0.203498 Bundy BN 0.397552 American Cancer Society 0.185854 vulvar carcinoma relative 0.190758 recurrent vulvar carcinoma 0.181549 vulvar squamous 0.170463 Primary groin irradiation 0.19228 vulvar carcinoma 0.421111 vulva maligno 0.200949 Radiat Oncol Biol 0.676441 DeVita VT Jr 0.292636 ISSVD Vulvar Oncology 0.241137 Obstet Gynecol Surv 0.191408 invasive vulvar carcinoma 0.181789 oncology group study 0.572234 Vulvar Oncology Subcommittee 0.241135 Thomas GM 0.191015 ganglios centinela 0.614725 Gynecol Oncol 0.971056 Rosenberg SA 0.195184 Database Syst Rev 0.701338 gynecologic oncology group 0.768104 Lawrence TS 0.197994	vulva with positive 0.200833 vulva treated with 0.19129 Markman MA 0.205496 vulva with emphasis 0.35831 Groin dissection versus 0.18662 vulva with 0.53285 vulval intraepithelial neoplasia 0.258055 Sedlis A 0.219223 equivalent to lymphadenectomy 0.170809 Eifel PJ 0.266136 Berek JS 0.206241 9th ed 0.206706 Clin Oncol 0.161496 vulvar intraepithelial neoplasia 0.93471 primary groin 0.238863 Oncol Biol Phys 0.700325 Radiation therapy 0.257312 Velden J 0.269821 groin irradiation versus 0.187219 Radical radiotherapy 0.168465 intraepithelial neoplasia with 0.201641 irradiation versus primary 0.185741 proper radiation technique 0.204024 intraepithelial neoplasia iii 0.18929	CLICK HERE
1864	National Cancer Institute	Html	es	Tratamiento de las neoplasias mieloproliferativas crónicas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mieloproliferativas crónicas.	mutación jak2 0.0546285 Campbell PJ 0.0405614 primary myelofibrosis 0.131535 polycythaemia vera 0.093088 Health Organization classification 0.0291993 have myelofibrosis with 0.0314259 Mesa RA 0.119444 or calr mutation 0.036061 with nonmutated jak2 0.0536842 myeloproliferative neoplasms 0.261769 thousand patients with 0.0269901 with polycythemia vera 0.195275 Vera Study Group 0.0949279 leucemia mielógena 0.0351738 polycythemia vera with 0.109106 stem cell transplantation 0.0588703 transfusion-dependent patients with 0.0283801 patients with philadelphia 0.0316383 myeloproliferative disorders 0.146587 vera with jak2v617f 0.038469 calr mutation 0.0482163 Leuk Lymphoma 0.0369689 with essential thrombocythemia 0.0866875 patients with 0.725855 Verstovsek S 0.0388869	essential thrombocythemia 0.44083 patients with primary 0.0790517 metaplasia with myelofibrosis 0.0416952 with myeloid metaplasia 0.913374 essential thrombocythaemia 0.0355199 CALR mutation status 0.0373736 Organization classification system 0.0297845 with primary myelofibrosis 0.0630012 jak2 or calr 0.0410501 sudores nocturnos 0.0340921 leucemia aguda 0.0337979 patients with myelofibrosis 0.203296 vera with recombinant 0.0414353 Thiele J 0.0617064 patients with polycythemia 0.16042 myelofibrosis with 0.580226 polycythemia vera 0.713605 Tefferi A 0.30746 thrombocythemia with substantially 0.0550099 Polycythemia Vera Study 0.106061 with substantially different 0.0495287 Clin Oncol 0.190573 neoplasms with nonmutated 0.0489374 essential thrombocythemia with 0.102281	CLICK HERE
1888	National Cancer Institute	Html	es	Tratamiento del linfoma de Hodgkin en adultos (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfoma de Hodgkin en adultos.	siguientes procedimientos 0.457132 células madre 0.773484 sedimentación globular vsg 0.343223 estadio iv 0.386067 siguientes elementos 0.335371 sudores nocturnos 0.52867 Elabora glóbulos 0.342317 siguientes afecciones 0.326701 siguientes especialistas 0.324883 siguientes tipos 0.334479 área cercanos.ampliar linfoma 0.414688 rayos x 0.318853 Hodgkin Lymphoma 0.444389 abdomen).ampliar linfoma 0.405698 enlace drugs approved 0.376199 largo plazo 0.313634 malformaciones congénitas 0.344911 escáner tep 0.32264 ondas sonoras 0.318768 estadio ie 0.448154 efectos tardíos 0.386184 cáncer.ampliar aspiración 0.320544	quimioterapia sistémica 0.399855 National Cancer Institute 0.315084 siguientes riesgos 0.314848 Instituto Nacional 0.326237 PDQ Tratamiento 0.422426 estadio iie 0.390253 líquido incoloro 0.32327 Herpes zóster 0.316049 estadio iiie 0.444346 siguientes problemas 0.333894 estadio e 0.345757 siguientes factores 0.326864 Physician Data Query 0.353006 siguientes subtipos 0.336371 siguientes sitios 0.33013 Leucemia mielógena aguda 0.327537 hodgkin clásico.ampliar célula 0.434672 estadio iiis 0.943901 células formadoras 0.331979 almacena glóbulos 0.343421 siguientes sumarios 0.346893 siguientes pruebas 0.333482	CLICK HERE
3425	National Cancer Institute	Html	es	Estrés psicológico y el cáncer	Hoja informativa que describe los efectos del estrés en el cuerpo, los resultados de investigaciones sobre la relación entre el estrés y el cáncer e información sobre cómo superar el estrés.	Sood AK 0.430056 care standards from 0.338514 determinadas hormonas 0.324248 Antoni MH 0.367904 tumor biology 0.324968 metastatic switch 0.319814 Dahmoush L 0.320856 psychological distress 0.325611 DeGeest K 0.320069 Dy SM 0.323303 Discovery Medicine 0.320658 estrés resultante 0.422988 biobehavioral signaling pathways 0.342266 peor calidad 0.321062 immune system 0.320953 McDonald PG 0.320742 Host factors 0.321766 Supportive Oncology 0.337163 Cox BF 0.320273 Psychological stress 0.329279 elevated tumor 0.324862 print march 0.323271	biobehavioral perspective 0.328519 familiar cercano 0.324843 tejidos adiposos mamarios 0.340834 sympathetic nervous system 0.335164 Lutgendorf SK 0.581508 Martinez KA 0.323343 ratones portadores 0.329629 PubMed Abstract 0.950792 killer cell activity 0.340076 carcinoma patients 0.32286 meta-analytic study 0.320949 Social isolation 0.322911 Lei X 0.320438 Priceman SJ 0.320893 peores resultados 0.32033 Clinical Oncology 0.442906 primary breast 0.321519 Segerstrom SC 0.320085 Psychological Bulletin 0.326317 largo tiempo 0.321876 bloqueadores beta 0.426953	CLICK HERE
15637	National Cancer Institute	Html	null	Research Funding Mechanisms	The NCI uses grants, cooperative agreements, and contracts to help stimulate and fund cancer research.			CLICK HERE
16831	National Cancer Institute	Html	en	Functional Genomics Research	NCI's Center for Cancer Genomics uses functional genomics to understand the impact of cancer genes and pathways, and how to target them effectively.	CTD² Network 0.438678 Wellcome Trust Sanger 0.539692 Cancer Target 0.513795 genome-wide techniques 0.446676 new ideas 0.464401 functional genomics 0.975263 genomic vulnerabilities 0.510701 functional genomics experiments 0.70252 clinical data 0.51781 abnormal proliferation 0.447258 functional cancer genomics 0.735243 functional genomic approaches 0.609867 new methods 0.442531 cutting-edge organoid 0.535662 Driver Discovery 0.445569 research community 0.441075 cancer care 0.532833 CTD2 Network 0.523145 structural genomics research 0.72197 large-scale genomic datasets 0.600198 cancer work 0.514288 cell models 0.464098 available drugs 0.442916 functional genomics research 0.95801 human tumors 0.440224	CRISPR-Cas9 technology 0.437797 particular genetic alterations 0.563867 gene perturbation experiments 0.559111 Cancer Research UK 0.609166 tumor organoid cultures 0.651279 cancer cells 0.526612 cancer cell lines 0.623629 publicly available bank 0.544919 Cancer Model Development 0.602943 genetic abnormalities 0.444289 new compounds 0.443968 Genome Characterization Pipeline 0.5568 structural genomics studies 0.680281 CCG researchers 0.496817 high-throughput drug screens 0.551758 clinical care 0.437267 publishing novel results 0.53823 patient biopsies 0.451112 petri dishes 0.439826 cancer genes 0.514196 cancer development 0.502413 next-generation cancer models 0.753989 Hubrecht Organoid Technology 0.640694 cancer biology 0.533186	CLICK HERE
16840	National Cancer Institute	Html	en	Companies Formed by PIs of the NCI Alliance for Nanotechnology in Cancer	The NCI Alliance for Nanotechnology in Cancer has continued to translate solutions from the bench to products. Find out the companies that have been formed by Alliance funded research.	clinical products 0.627038 Alliance members 0.614849 academic laboratories 0.654334 for-profit partners 0.714957 start-ups 0.300298 clinical communities 0.60175 venture capital funds 0.950483 investigators 0.301645 partnerships 0.289977 start-up companies 0.650807 patents 0.29414 large pharmaceutical companies 0.926075	translational research 0.68727 significant investment 0.618191 Alliance PIs 0.780886 efficient development 0.679103 IP 0.327964 Alliance model 0.651092 services 0.276826 start-up companies. 0.723832 technologies 0.28746 biotechnology firms 0.63767 form 0.28731 discoveries 0.300415	CLICK HERE